
Dyne Therapeutics Investor Relations Material
Latest events

Status Update
Dyne Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dyne Therapeutics Inc
Access all reports
Dyne Therapeutics Inc. is a biotechnology firm engaged in the development of innovative therapeutics aimed at addressing genetically driven muscle diseases. Established in 2017 and based in Waltham, Massachusetts, the company primarily focuses on advancing a portfolio of muscle disease therapeutics. These efforts include targeting conditions such as myotonic dystrophy type 1, duchenne muscular dystrophy, facioscapulohumeral dystrophy, and other rare skeletal, cardiac, and metabolic muscle diseases. Dyne Therapeutics utilizes its proprietary FORCE platform, which is designed to enhance the delivery of disease-modifying therapeutics directly to muscle tissue. Its shares are listed on the Nasdaq.
Key slides for Dyne Therapeutics Inc


Study Update
Dyne Therapeutics Inc


Study Update
Dyne Therapeutics Inc
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
DYN
Country
🇺🇸 United States